CN103830722A - Clostridium perfringens beta toxin genetic engineering vaccine and application thereof - Google Patents
Clostridium perfringens beta toxin genetic engineering vaccine and application thereof Download PDFInfo
- Publication number
- CN103830722A CN103830722A CN201410117384.5A CN201410117384A CN103830722A CN 103830722 A CN103830722 A CN 103830722A CN 201410117384 A CN201410117384 A CN 201410117384A CN 103830722 A CN103830722 A CN 103830722A
- Authority
- CN
- China
- Prior art keywords
- toxin
- target gene
- pet28a
- clostridium perfringens
- pcr product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710124951 Phospholipase C Proteins 0.000 title claims abstract description 61
- 241000193468 Clostridium perfringens Species 0.000 title claims abstract description 28
- 229960005486 vaccine Drugs 0.000 title claims abstract description 17
- 238000010353 genetic engineering Methods 0.000 title claims 4
- 239000013612 plasmid Substances 0.000 claims abstract description 17
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229940033663 thimerosal Drugs 0.000 claims abstract description 8
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000000746 purification Methods 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 13
- 230000009465 prokaryotic expression Effects 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- 238000001742 protein purification Methods 0.000 claims description 6
- 238000007400 DNA extraction Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 claims description 4
- 239000011543 agarose gel Substances 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 229940071127 thioglycolate Drugs 0.000 claims 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 244000309714 Clostridium perfringens type C Species 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 7
- 206010012735 Diarrhoea Diseases 0.000 abstract description 3
- 235000019687 Lamb Nutrition 0.000 abstract description 3
- 244000309466 calf Species 0.000 abstract description 3
- 210000003022 colostrum Anatomy 0.000 abstract description 3
- 235000021277 colostrum Nutrition 0.000 abstract description 3
- 208000029182 enterotoxemia Diseases 0.000 abstract description 3
- 230000002008 hemorrhagic effect Effects 0.000 abstract description 3
- 210000003000 inclusion body Anatomy 0.000 abstract description 2
- 230000035935 pregnancy Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 208000037931 necrotizing enteritis Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 4
- 229960002064 kanamycin sulfate Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000028744 lysogeny Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 238000009631 Broth culture Methods 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical class OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 2
- 101710150593 Protein beta Proteins 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101000942941 Arabidopsis thaliana DNA ligase 6 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241001134775 Lysinibacillus fusiformis Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种产气荚膜梭菌β毒素基因工程苗及其应用；是利用β毒素特异性引物,复活C型产气荚膜梭菌菌种，PCR扩增获得β毒素基因片段（930bp）连接到PET-28a（+）质粒上，然后将重组质粒导入受体菌株，成功构建重组菌株BL21(DE3)-β；重组的菌株BL21(DE3)以包涵体的形式高效表达β毒素；将β毒素蛋白与白油佐剂以体积比为1:1的比例进行乳化，加入0.01%的硫柳汞制得疫苗。该疫苗用于免疫妊娠后期的母畜，新生仔畜通过初乳获得被动免疫，能有效预防幼畜出血性坏死性肠炎(羔羊痢疾、犊牛肠毒血症、仔猪红痢等)；通过进行免疫保护效力实验证明该疫苗对兔的保护力达到了100%。
The present invention relates to a Clostridium perfringens beta toxin genetically engineered seedling and its application; the beta toxin gene fragment (930bp ) was connected to the PET-28a (+) plasmid, and then the recombinant plasmid was introduced into the recipient strain, and the recombinant strain BL21(DE3)-β was successfully constructed; the recombinant strain BL21(DE3) highly expressed β toxin in the form of inclusion bodies; The beta toxin protein and white oil adjuvant were emulsified at a volume ratio of 1:1, and 0.01% thimerosal was added to prepare the vaccine. The vaccine is used to immunize female animals in the late pregnancy, and newborn animals can be passively immunized through colostrum, which can effectively prevent hemorrhagic necrotizing enteritis (lamb dysentery, calf enterotoxemia, piglet red diarrhea, etc.); through immunization The protective efficacy experiment proved that the vaccine had 100% protective effect on rabbits.
Description
(1) technical field
The present invention relates to a kind of Sequencing of Beta Toxin Gene of Clostridium perfringens engineered vaccine and application thereof.
(2) background of invention
Bacillus perfringens (Clostridium perfringens) is a kind of Gram-positive, generation brood cell, strictly anaerobic and the bacillus fusiformis that forms special pod membrane.The ability that produces four kinds of lethal toxin (α, β, ε, ι toxin) according to it, is divided into five types, i.e. five types of A, B, C, D, E.Bacillus perfringens β toxin is necrosis, the lethal toxin being produced by bacillus perfringens Type B and C type bacterial strain, the necrosis that can produce hemolytic, and its toxic action shows on intestinal villi, can cause the necrotic enteritis of humans and animals.
China is animal husbandry big country, and pig, cattle, sheep are Main Economic domestic animals, and young stock diarrhoea is the important epidemic disease that affects animal husbandry development.The young stock hemorrhagic necrosis enteritis (lamb dysentery, calf enterotoxemia, piglet red dysentery etc.) being caused by bacillus perfringens β toxin, popular very serious in the vast pastoral area of China, there is higher M & M, caused huge economic loss to animal husbandry.The Drug therapy of young stock diarrhoea not only expensive, take a lot of work, and effect is bad, more, because pathogenic bacterium drug resistance strain increases increasingly, medication is often invalid, thereby immunoprophylaxis is the optimum selection of this class epidemic disease of control.There is pathogenic hidden danger in bacillus perfringens toxoid vaccine clinically, and recombinant vaccine is safe and output is high, purity is high.
(3) summary of the invention
In order to address the above problem, the invention provides a kind of Sequencing of Beta Toxin Gene of Clostridium perfringens engineered vaccine and application thereof, possess the advantages such as immunity is strong, specific aim good, have no side effect, safety is good.
A kind of Sequencing of Beta Toxin Gene of Clostridium perfringens engineered vaccine, is that the ratio taking volume ratio as 1:1 is carried out emulsifying by β toxin protein and white-oil adjuvant, adds 0.01 gram of thimerosal to make in every 100ml emulsion; The preparation method of described β toxin protein comprises the following steps:
1) strain brings back to life and template preparation
Be inoculated in a blood plate culture medium 40 DEG C of anaerobism (88%N with inoculating loop picking C type bacillus perfringens strain
2, 7%H
2, 5%CO
2) cultivation 36h.Containing 7-8 milliliter THIOGLYCOLLIC ACID salt broth (FT) in vitro 37 DEG C of anaerobism are cultivated 12h in one to get single colony inoculation, and the culture fluid of getting 1～5ml extracts DNA according to the explanation of DNA extraction test kit, as the template of amplifying target genes.
2) clone of β toxin gene
Carry out pcr amplification genes of interest according to the gene order design primer of β toxin in GenBank, amplified production, after agarose gel electrophoresis, reclaims amplified production;
Primer1:GGAATTCAATGATATAGGTAAAACTAC; (shown in SEQ.ID.N03)
Shown in Primer2:CCTCGAGTTAAATAGCTGTTACTTTGTGAGT(SEQ.ID.N04)
3) build prokaryotic expression carrier pET28a-β
Genes of interest PCR product and expression vector pET28a are all used to Eco RI and Xho I enzyme action; The genes of interest PCR product and the expression vector pET28a that after enzyme action, reclaim are respectively carried out to purification.The genes of interest PCR product of purification is connected with carrier pET28a, obtains recombiant plasmid pET28a-β.After pET28a-β is mixed with BL21 (DE3) competent cell, transform, obtain recombinant bacterial strain BL21 (DE3)-β.
4) prokaryotic expression of β toxin gene, protein purification
With the IPTG of 0.6mM, 37 DEG C, to recombinant bacterium abduction delivering 12h, the purified β toxin protein that obtains.
The preparation method that the invention still further relates to a kind of Sequencing of Beta Toxin Gene of Clostridium perfringens engineered vaccine, comprises the following steps:
1) strain brings back to life and template preparation
Be inoculated in a blood plate culture medium 40 DEG C of anaerobism (88%N with inoculating loop picking C type bacillus perfringens strain
2, 7%H
2, 5%CO
2) cultivation 36h.Containing 7-8 milliliter THIOGLYCOLLIC ACID salt broth (FT) in vitro 37 DEG C of anaerobism are cultivated 12h in one to get single colony inoculation, and the culture fluid of getting 1～5ml extracts DNA according to the explanation of DNA extraction test kit, as the template of amplifying target genes.
2) clone of β toxin gene
Carry out pcr amplification genes of interest according to the gene order design primer of β toxin in GenBank, amplified production, after agarose gel electrophoresis, reclaims amplified production;
Primer1:GGAATTCAATGATATAGGTAAAACTAC; (shown in SEQ.ID.N03)
Shown in Primer2:CCTCGAGTTAAATAGCTGTTACTTTGTGAGT(SEQ.ID.N04)
3) build prokaryotic expression carrier pET28a-β
Genes of interest PCR product and expression vector pET28a are all used to Eco RI and Xho I enzyme action; The genes of interest PCR product and the expression vector pET28a that after enzyme action, reclaim are respectively carried out to purification.The genes of interest PCR product of purification is connected with carrier pET28a, obtains recombiant plasmid pET28a-β.After pET28a-β is mixed with BL21 (DE3) competent cell, transform, obtain recombinant bacterial strain BL21 (DE3)-β.
4) prokaryotic expression of β toxin gene, protein purification
With the IPTG of 0.6mM, 37 DEG C, to recombinant bacterium abduction delivering 12h, the purified β toxin protein that obtains.
5) β toxin gene engineering Seedling preparation
By the β toxin protein preparing in above-mentioned steps and white-oil adjuvant, the ratio taking volume ratio as 1:1 is carried out emulsifying, adds 0.01 gram of thimerosal to obtain in every 100ml emulsion.
The invention still further relates to the application of a kind of Sequencing of Beta Toxin Gene of Clostridium perfringens engineered vaccine in the piglet red dysentery that causes because of bacillus perfringens β toxin of prevention:
The Sequencing of Beta Toxin Gene of Clostridium perfringens engineering Seedling of preparing in antenatal 30 days of farrowing sow and the present invention of each intramuscular injection on the 15th, each 6ml/ only, for immune sow heavy in pig, newborn piglet obtains passive immunity, prevention piglet red dysentery by sucking food colostrum.
Beneficial effect
Prepared by these research and development safe, immunity is strong, therapeutic effect good, the Sequencing of Beta Toxin Gene of Clostridium perfringens engineered vaccine having no side effect, for the female animal of immune latter half of gestation, newborn animal obtains passive immunity by colostrum, can effectively prevent young stock hemorrhagic necrosis enteritis (lamb dysentery, calf enterotoxemia, piglet red dysentery etc.).
(4) brief description of the drawings
Fig. 1 is the destination protein β toxin SDS-PAGE electrophoretogram giving expression to.
From scheming, can find out that the destination protein size giving expression to is that 38KD and β toxin are in the same size, illustrates and has successfully given expression to destination protein.
Fig. 2 is preparation technology's flow process of this gene engineering vaccine
(5) detailed description of the invention
1, strain brings back to life and template preparation
With (the National Collection of Type Cult μ res Britain microorganism fungus kind preservation center preservation of inoculating loop picking C type bacillus perfringens strain, NCTC3180) be inoculated in a blood plate culture medium (after 100 ml distilled waters, 1 gram of glucose and the sterilizing of 3.8 grams of bean agar powders, adding 5 milliliters of Sheep Bloods to divide installs on six blood plates) upper, 40 DEG C of anaerobism (88%N
2, 7%H
2, 5%CO
2) cultivation 36h.Get single colony inoculation in one containing 7-8 milliliter THIOGLYCOLLIC ACID salt broth (FT) (medium component is general) in vitro, 37 DEG C of anaerobism are cultivated 12h, the culture fluid of getting 1～5ml illustrates and extracts DNA according to DNA extraction test kit (the precious biotech firm in Dalian), as the template of amplifying target genes.
2, the structure of the Cloning and Expression carrier of β toxin gene
(1) design of primer
As follows according to the primer of the gene order of β toxin in GenBank (accession number L13198, its nucleotide sequence is as shown in SEQ.ID.N01) design:
Primer1:GGAATTCAATGATATAGGTAAAACTAC;
Primer2:CCTCGAGTTAAATAGCTGTTACTTTGTGAGT
(2) clone of β toxin gene and recovery
The DNA extracting taking the first step is as template, and (reaction system is as follows: forward primer 2 μ l, downstream primer 2 μ l for the genes of interest that amplified production is 930bp, cDNA2 μ l, dNTP1 μ l, 10X pf μ B μ ffer5 μ l, Pf μ pyro polymerase 0.4 μ l, ddH2O polishing to 50 μ l).Pcr amplification product, after agarose gel electrophoresis, reclaims test kit (the precious biotech firm in Dalian) with DNA gel and reclaims object band.
(3) enzyme action genes of interest PCR product and expression vector pET28a
Genes of interest PCR product is used to EcoR I and Xho I enzyme action, and (reaction system is: PCR product 20 μ l, EcoR I1 μ l, Xho I1 μ l, 10X Buffer Tango5 μ l, ddH
2o23 μ l) reacts 4h in 37 DEG C of thermostat water baths; By expression vector pET28a, with EcoR I and Xho I enzyme action, (system is: pET28a1 μ g, EcoR I1 μ l, Xho I1 μ l, 10X Buffer Tango5 μ l, ddH
2o complements to 50 μ and l) in 37 DEG C of thermostat water baths, reacts 4h.
(4) reclaim genes of interest PCR product and carrier and carry out purification
After enzyme action finishes, reclaim respectively genes of interest PCR product and carrier and carry out purification by 1% agarose gel electrophoresis.The process of glue recovery and purification genes of interest PCR product and carrier is as follows:
A. from agarose gel, cut off respectively the blob of viscose that contains genes of interest PCR product and carrier and weigh.
B. add the B μ fferB2 of 3 times of blob of viscose weight, 50 DEG C of water-bath 5min.
C. sol solutions is moved in adsorption column, the centrifugal 30s of 8000g, outwells the liquid in collecting pipe.
D. add 500 μ lWash Solution, the centrifugal 30s of 9000g, outwells the liquid in collecting pipe, repeats this process once.
E. by another suction attached column in the centrifugal 1min of 9000g, then put into a clean 1.5ml centrifuge tube, add 40 μ l Elution Buffur in adsorbed film central authorities, room temperature leaves standstill 1min, then preserves that glue in pipe reclaims and the genes of interest PCR product of purification.
(5) preparation of recombiant plasmid
The genes of interest PCR product that reclaims purification is connected with carrier pET28a, and reaction system is: PCR product 5 μ l, expression vector pET28a5 μ l, 10X T4DNA ligase Buffer2 μ l, T4DNA ligase1 μ l, ddH
2o7 μ l reacts 2h and carries out coupled reaction and obtain recombiant plasmid in 16 DEG C of thermostat water baths.
(6) preparation of recombinant bacterial strain and the qualification of positive recombiant plasmid
Recombiant plasmid is proceeded to BL21(DE3) competent cell (purchased from Divine Land, Beijing red autumnal leaves Science and Technology Ltd.) in: recombiant plasmid and BL21(DE3) competent cell adds in centrifuge tube by 1:5 volume ratio, leaves standstill 20min under condition of ice bath.Be placed in 42 DEG C of thermostat water bath heat shock 90s again, then under condition of ice bath, leave standstill 5min, add 800 μ l LB culture medium, 37 DEG C of constant-temperature tables again in centrifuge tube, 200r/m cultivates 30min; So far recombiant plasmid has been proceeded to recombinant bacterial strain BL21(DE3).Draw competent cell that 200 μ l have transformed and be added to and contain on the LB agar culture medium of kanamycin sulfate that concentration is 34 μ g/mL, cell is evenly coated with and is opened.Flat board is placed in to 37 DEG C and is cultured to liquid and is absorbed, be inverted dull and stereotyped, 37 DEG C of incubated overnight.Sterile working's picking list colony inoculation is in containing the LB fluid medium increasing bacterium that concentration is the kanamycin sulfate of 34 μ g/mL, and 37 DEG C of shaken cultivation 12-14h, illustrate and extract plasmid according to plasmid extraction kit (Tai'an Bo Ao biotech company).
Nci I/BamH I and 37 DEG C of enzyme action 3h of BamH I/Not I restricted enzyme for the plasmid DNA that extraction obtains, enzyme action system 10ul: the each 0.5ul of restricted enzyme, recombiant plasmid 6ul, 10 × buffer1ul, ddH
2o2ul.
Enzyme action product is observed enzyme action segment in 1% agarose gel, determines positive recombiant plasmid, send Jin Site Engineering Co., Ltd to carry out nucleotide sequencing.The homology that Blast compares surveyed β toxin complete genome sequence online and GenBank has delivered corresponding sequence is more than 98%.
3, the prokaryotic expression of β toxin gene, protein purification and specific detection
Picking recombinant bacterial strain BL21(DE3) single bacterium colony (lysogeny broth nutrient media components: Tryptone2g in the test tube of 5mL lysogeny broth culture medium, Yeast extract1g, Nacl2g is dissolved in the kanamycin sulfate that adds 34 μ g in the every 1mLlysogeny broth of 200mL deionized water culture medium) 37 DEG C, 220rpm/min incubated overnight.The bacterium liquid of cultivation is inoculated in 200ml lysogeny broth culture medium (adding the kanamycin sulfate of 34 μ g in every 1mL lysogeny broth culture medium) by the volume ratio of 1:100,37 DEG C, 180rpm/min amplification culture.In the time that OD value reaches 0.6 left and right, the IPTG that interpolation final concentration is 0.6mM, 37 DEG C, 120rpm/min induces 12h.The albumen of expressing is present in thalline with the form of inclusion body, collects thalline and uses PBS buffer (component: NaCl8g, KCl0.2g, Na
2hPO
412H
2o3.58g, KH
2pO
40.27g is dissolved in 1000mL deionized water) suspend.The albumen of ultrasonication thalline to obtain expressing: ultrasonication thalline in ice bath, power 200W, 99 circulations (ultrasonic 3S, suspending 5S is a circulation).Ultrasonic complete, 8000rpm/min, 4 DEG C, centrifugal 15min, cleer and peaceful precipitation in collection.Destination protein β toxin is present in supernatant, gets supernatant and prepares purification.By Ni-Agarose His label protein purification column (Nanjing Genscript Biotechnology Co., Ltd.) purification, obtain purer β toxin.After purification, sample carries out SDS-PAGE electrophoresis, and detects the specificity of expressing protein by Western blot.
4, β toxin gene engineering Seedling preparation
By the β toxin protein of producing and white-oil adjuvant, the ratio taking volume ratio as 1:1 is carried out emulsifying, adds 0.01 gram of thimerosal in every 100ml emulsion, obtains Sequencing of Beta Toxin Gene of Clostridium perfringens engineering Seedling.
5, β toxin gene engineering Seedling safety verification
With 4 of the rabbit of body weight 1.5-2 kilogram, 5 milliliters of each intramuscular injection vaccines, observe 10, all strong living, injection site does not necrose.
6, β toxin gene engineering Seedling steriling test
Carry out asepsis growth with reference to 301 pages of " People's Republic of China's veterinary biologics quality standard " (calendar year 2001 version) annex.
7, β toxin gene engineering Seedling thimerosal assay
Carry out with reference to 313 pages of " People's Republic of China's veterinary biologics quality standard " (calendar year 2001 version) annex, meet " pertinent regulations of goods inspection " (thimerosal content is no more than 0.01%).
8, β toxin gene engineering Seedling immune protection effectiveness test
Get 10 of 1.5-2kg Healthy Rabbits; be divided into matched group and experimental group; every group each 5, the β toxin gene engineering Seedling of every intramuscular injection 2ml of experimental group, the physiological saline solution of every each intramuscular injection equivalent of matched group; after 21 days; 10 rabbits are injected respectively 2ml bacillus perfringens β toxin, observe 3-5 day, and 5 rabbits of matched group are all dead; 5 rabbits of immune group are all not dead, illustrate that this vaccine has reached 100% to the protection of rabbit.
9, application
There is more serious pig factory certain piglet red dysentery is sick, farrowing sow is divided into two groups and is respectively immune group and nonimmune group, every group each 20; The farrowing sow of immune group was in antenatal 30 days and Sequencing of Beta Toxin Gene of Clostridium perfringens engineering Seedling of each intramuscular injection on the 15th, and each 6ml is as immune group; Nonimmune group of vaccinate not, separates raising the sow of immune group and the sow of nonimmune group simultaneously.Result shows, the piglet that the sow of immune group produces occurs without piglet red dysentery phenomenon, but not in the piglet that every sow of immune group produces, has piglet red dysentery phenomenon to occur.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410117384.5A CN103830722A (en) | 2014-03-27 | 2014-03-27 | Clostridium perfringens beta toxin genetic engineering vaccine and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410117384.5A CN103830722A (en) | 2014-03-27 | 2014-03-27 | Clostridium perfringens beta toxin genetic engineering vaccine and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830722A true CN103830722A (en) | 2014-06-04 |
Family
ID=50794823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410117384.5A Pending CN103830722A (en) | 2014-03-27 | 2014-03-27 | Clostridium perfringens beta toxin genetic engineering vaccine and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830722A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104829712A (en) * | 2015-04-23 | 2015-08-12 | 山东农业大学 | C and D type C.perfringens antitoxin serum and preparation method thereof |
| CN108578686A (en) * | 2018-04-23 | 2018-09-28 | 武汉中拓康明生物科技有限公司 | A method of preparing clostridiosis of sheep genetic engineering subunit vaccine |
| CN109078178A (en) * | 2018-08-02 | 2018-12-25 | 中国兽医药品监察所 | A kind of C. perfringens beta toxin recombinant subunit vaccine and its production method |
| CN113702640A (en) * | 2021-06-16 | 2021-11-26 | 宁夏大学 | Indirect ELISA method for clostridium perfringens beta 1 toxin antibody |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432579A (en) * | 2013-09-12 | 2013-12-11 | 山东农业大学 | Preparation method of lamb-dysentery clostridium perfringens type B toxoid vaccine |
-
2014
- 2014-03-27 CN CN201410117384.5A patent/CN103830722A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432579A (en) * | 2013-09-12 | 2013-12-11 | 山东农业大学 | Preparation method of lamb-dysentery clostridium perfringens type B toxoid vaccine |
Non-Patent Citations (1)
| Title |
|---|
| ADALGISA MILACH等: "Production and characterization of Clostridium perfringens recombinant b toxoid", 《ANAEROBE》, vol. 18, 24 January 2012 (2012-01-24), pages 363 - 365 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104829712A (en) * | 2015-04-23 | 2015-08-12 | 山东农业大学 | C and D type C.perfringens antitoxin serum and preparation method thereof |
| CN104829712B (en) * | 2015-04-23 | 2018-03-27 | 山东农业大学 | C, D types C.perfringens antitoxic serum and preparation method thereof |
| CN108578686A (en) * | 2018-04-23 | 2018-09-28 | 武汉中拓康明生物科技有限公司 | A method of preparing clostridiosis of sheep genetic engineering subunit vaccine |
| CN108578686B (en) * | 2018-04-23 | 2022-07-01 | 杨凌凯瑞生物科技有限公司 | Method for preparing genetic engineering subunit vaccine for clostridium aegypti |
| CN109078178A (en) * | 2018-08-02 | 2018-12-25 | 中国兽医药品监察所 | A kind of C. perfringens beta toxin recombinant subunit vaccine and its production method |
| CN109078178B (en) * | 2018-08-02 | 2020-08-04 | 中国兽医药品监察所 | Clostridium perfringens β toxin recombinant subunit vaccine and production method thereof |
| CN113702640A (en) * | 2021-06-16 | 2021-11-26 | 宁夏大学 | Indirect ELISA method for clostridium perfringens beta 1 toxin antibody |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830722A (en) | Clostridium perfringens beta toxin genetic engineering vaccine and application thereof | |
| CN109467606A (en) | A kind of Escherichia coli enterotoxin STa-LTB-STb fusion protein and its encoding gene and application | |
| CN106929451A (en) | One plant of Streptococcus suis and its application | |
| CN107753940B (en) | Clostridium perfringens epsilon toxin recombinant subunit vaccine and production method thereof | |
| CN100579578C (en) | Pyloric spiral bacillus antigen recombinant vaccine | |
| CN103421832B (en) | Comprise yolk antibody and the preparation and application of florfenicol Drug Resistance Gene Associated Proteins | |
| CN115991749A (en) | A porcine infectious pleuropneumonia-pasteurella multocida dual subunit vaccine | |
| CN104530230B (en) | A kind of duck hepatitis A virus VP1 GFPs and its application | |
| CN103830747A (en) | Genetically engineered vaccine of epsilon toxin of clostridium perfringens and application thereof | |
| CN105148262B (en) | A kind of preparation method of five bivalent inactivated vaccine of haemophilus parasuis | |
| CN109609418B (en) | Erysipelothrix rhusiopathiae and application thereof | |
| CN103495159B (en) | The preparation method of flavobacterium columnare genetic vaccine | |
| CN102363762A (en) | Transbacillus-derived α-amylase gene recombinant lactobacillus and its products and applications | |
| CN103861094A (en) | Clostridium perfringen alpha toxin genetic engineering vaccine and application thereof | |
| CN102676421B (en) | Bordetella bronchiseptica gene deletion strain, vaccine prepared from Bordetella bronchiseptica gene deletion strain and application | |
| CN105524177A (en) | Mycobacterium tuberculosis specific fusion protein, and encoding gene and application thereof | |
| CN102676570B (en) | Recombinant bacillus subtilis immunoglobulin binding protein functional-domain expression vector and application thereof | |
| CN107158371A (en) | A kind of gene engineered subunit bigeminy oral vaccine | |
| CN107982527A (en) | Applications of the outer membrane protein V P1243 in vibrio infection is prevented | |
| CN102698260B (en) | Preparation method and application of subunit vaccine for preventing Staphylococcus-induced mammitis of goats | |
| CN101940786A (en) | Application of immunogenic protein gene PilA of haemophilus parasuis | |
| CN105602981A (en) | Preparation method and application of porcine epidemic diarrhea virus genetic engineering subunit oral combined vaccine | |
| CN102206258A (en) | NmpC subunit vaccine of salmonella paratyphi A and preparation method thereof | |
| CN105713096B (en) | A kind of preparation and application of the ATT fusion protein preventing infection of staphylococcus aureus | |
| CN115819625B (en) | Escherichia coli tetravalent antigen fusion polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140604 |